These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Determination of globotriaosylceramide in plasma and urine by mass spectrometry. Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207 [TBL] [Abstract][Full Text] [Related]
7. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. Abaoui M; Boutin M; Lavoie P; Auray-Blais C Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248 [TBL] [Abstract][Full Text] [Related]
8. High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. Auray-Blais C; Lavoie P; Abaoui M; Côté AM; Boutin M; Akbari A; Levin A; Mac-Way F; Tr Clarke J Clin Chim Acta; 2020 Feb; 501():234-240. PubMed ID: 31778673 [TBL] [Abstract][Full Text] [Related]
9. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. Auray-Blais C; Cyr D; Mills K; Giguère R; Drouin R J Inherit Metab Dis; 2007 Feb; 30(1):106. PubMed ID: 17171433 [TBL] [Abstract][Full Text] [Related]
10. A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients. Alharbi FJ; Geberhiwot T; Hughes DA; Ward DG J Am Soc Mass Spectrom; 2016 Apr; 27(4):719-25. PubMed ID: 26797827 [TBL] [Abstract][Full Text] [Related]
11. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry. Lavoie P; Boutin M; Abaoui M; Auray-Blais C Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162 [TBL] [Abstract][Full Text] [Related]
12. Analysis of globotriaosylceramide (Gb Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250 [TBL] [Abstract][Full Text] [Related]
13. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231 [TBL] [Abstract][Full Text] [Related]
14. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222 [TBL] [Abstract][Full Text] [Related]
15. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study. Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071 [TBL] [Abstract][Full Text] [Related]
16. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437 [TBL] [Abstract][Full Text] [Related]
17. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368 [TBL] [Abstract][Full Text] [Related]
18. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Barr C; Clarke JT; Ntwari A; Drouin R; Auray-Blais C Mol Genet Metab; 2009 Aug; 97(4):278-83. PubMed ID: 19464216 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031 [TBL] [Abstract][Full Text] [Related]
20. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease. Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]